CN117460748A - 抗nkg2a抗体和组合物 - Google Patents

抗nkg2a抗体和组合物 Download PDF

Info

Publication number
CN117460748A
CN117460748A CN202280039227.XA CN202280039227A CN117460748A CN 117460748 A CN117460748 A CN 117460748A CN 202280039227 A CN202280039227 A CN 202280039227A CN 117460748 A CN117460748 A CN 117460748A
Authority
CN
China
Prior art keywords
amino acid
antibody
seq
acid sequence
nkg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039227.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·W·汉森
F·K·乌伦布罗克
N·迪特里希
A·沃索
M·M·格兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN117460748A publication Critical patent/CN117460748A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280039227.XA 2021-06-01 2022-05-31 抗nkg2a抗体和组合物 Pending CN117460748A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
US63/195,470 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
CN117460748A true CN117460748A (zh) 2024-01-26

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039227.XA Pending CN117460748A (zh) 2021-06-01 2022-05-31 抗nkg2a抗体和组合物

Country Status (17)

Country Link
US (2) US12012450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347651A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520577A (cg-RX-API-DMAC7.html)
KR (1) KR20240016991A (cg-RX-API-DMAC7.html)
CN (1) CN117460748A (cg-RX-API-DMAC7.html)
AR (1) AR126001A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022286617A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222040A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003562A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015982A2 (cg-RX-API-DMAC7.html)
IL (1) IL308695A (cg-RX-API-DMAC7.html)
MX (1) MX2023014320A (cg-RX-API-DMAC7.html)
PE (1) PE20240372A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553123A1 (cg-RX-API-DMAC7.html)
TW (1) TW202313683A (cg-RX-API-DMAC7.html)
WO (1) WO2022253805A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN121358774A (zh) * 2023-06-21 2026-01-16 科望(苏州)生物医药科技有限公司 与nkg2a结合的抗体或抗原结合片段及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN116693685A (zh) * 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof

Also Published As

Publication number Publication date
US12012450B2 (en) 2024-06-18
JP2024520577A (ja) 2024-05-24
CA3222040A1 (en) 2022-12-08
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
MX2023014320A (es) 2023-12-13
US20240294638A1 (en) 2024-09-05
EP4347651A1 (en) 2024-04-10
KR20240016991A (ko) 2024-02-06
CL2023003562A1 (es) 2024-07-12
AR126001A1 (es) 2023-08-30
BR112023024772A2 (pt) 2024-02-15
AU2022286617A1 (en) 2023-12-21
WO2022253805A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US20220389100A1 (en) 2022-12-08
PE20240372A1 (es) 2024-03-05
CO2023015982A2 (es) 2024-01-15

Similar Documents

Publication Publication Date Title
CN115023439B (zh) 抗cd73抗体
US12012450B2 (en) Anti-NKG2A antibodies and compositions
US12252539B2 (en) Anti-FLT3 antibodies and compositions
KR20240168451A (ko) 항-pvrig 항체, 이의 약제학적 조성물 및 이의 용도
US11807688B2 (en) Anti-AXL antibodies and compositions
US20210214454A1 (en) Anti-cd40 antibodies and compositions
HK40106092A (en) Anti-nkg2a antibodies and compositions
RU2837590C9 (ru) Антитела против axl и композиции
RU2837590C1 (ru) Антитела против axl и композиции
RU2836004C1 (ru) Антитела и композиции против flt3
HK40081002A (en) Anti-axl antibodies and compositions
HK40084729A (en) Anti-flt3 antibodies and compositions
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106092

Country of ref document: HK